journal
MENU ▼
Read by QxMD icon Read
search

Journal of Oncology Pharmacy Practice

journal
https://www.readbyqxmd.com/read/28565936/osimertinib-a-third-generation-tyrosine-kinase-inhibitor-for-treatment-of-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-with-the-acquired-thr790met-mutation
#1
Meredith K Bollinger, Amanda S Agnew, Gerard P Mascara
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy. The T790M mutation is an acquired resistance mechanism found in over half of patients with NSCLC progressing on first-generation TKIs. First- and second-generation TKIs do not inhibit the T790M mutation at clinically relevant concentrations. Osimertinib is selective for mutated forms of EGFR, including the TKI-sensitizing mutations L858R and exon 19 deletions, as well as the acquired T790M resistance mutation...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28565935/why-overall-survival-and-not-progression-free-survival-improves-in-era-of-program-death-inhibitors
#2
Reyad Dada
No abstract text is available yet for this article.
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28554241/interdisciplinary-implementation-of-tacrolimus-intravenous-standard-concentration-in-hematopoietic-stem-cell-transplantation-recipients
#3
Brandon R Shank, Melissa Deaver, Angela Baker, Alan L Myers, Yan-Ping Zhang, Brent Anderegg, Roland Bassett, Michael Westmoreland
Purpose Reduction in waste of intravenous (IV) tacrolimus, an immunosuppressant used to prevent graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients, was evaluated after standardizing the concentration. Methods A single-center, retrospective cohort study at a large academic comprehensive cancer center was performed comparing patient-specific intravenous tacrolimus doses (tacrolimus doses in 50, 100, or 250 mL of normal saline based on manufacturer's recommended concentration) to tacrolimus intravenous standard concentration (tacrolimus 1 mg in 250 mL of normal saline) continuous intravenous infusion titrated to prescribed dose...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28523950/levocarnitine-and-vitamin-b-complex-for-the-treatment-of-pegaspargase-induced-hepatotoxicity-a-case-report-and-review-of-the-literature
#4
Alison Blackman, Alyssa Boutin, Alexei Shimanovsky, William J Baker, Nicholas Forcello
Asparaginase is a chemotherapeutic agent that is commonly used in combination with other medications for the treatment of acute lymphoblastic leukemia. An adverse effect of asparaginase includes hepatotoxicity, which can lead to severe liver failure and death. Several reports have documented successful treatment of asparaginase-induced hepatotoxicity using levocarnitine (l-carnitine) and vitamin B complex. Herein, we report a patient with acute lymphoblastic leukemia that experienced acute liver injury following pegaspargase administration...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28509614/the-impact-of-pharmacist-telephone-calls-after-discharge-on-satisfaction-of-oncology-patients-a-randomized-controlled-study
#5
Sewar S Salmany, Lujeen Ratrout, Abdallah Amireh, Randa Agha, Noor Nassar, Nour Mahmoud, Dalia Rimawi, Lama Nazer
Purpose The aim of the study was to determine the impact of telephone follow-up calls on satisfaction in oncology patients after hospital discharge. Method A randomized controlled study, in which patients were randomized into two groups: The experimental group with the telephone follow-up (TFU) calls (intervention) and the control group (no intervention). The telephone follow-up call was conducted within 72 h after discharge. During the call, patients were asked about their medications, namely, whether they received them, understood how to take them, and whether they developed any medication-related adverse effect...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28509613/impact-of-a-specialty-pharmacy-case-management-service-on-adherence-in-patients-receiving-oral-antineoplastic-agents
#6
Grant Middendorff, Rachel Elsey, Brian Lounsbery, Roxanne Chadwell
Background Patients receiving treatment with oral antineoplastic agents encounter several barriers to adherence, which may include high medication costs, limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. Although several previous studies have examined patient adherence to oral antineoplastic agents, few have examined the impact of a specialty pharmacy case management service...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28457192/assessment-of-adherence-and-relative-dose-intensity-with-oral-chemotherapy-in-oncology-clinical-trials-at-an-academic-medical-center
#7
Jeff A Engle, Anne M Traynor, Toby C Campbell, Kari B Wisinski, Noelle LoConte, Glenn Liu, George Wilding, Jill M Kolesar
Background/Aims Oral chemotherapy is increasingly utilized leaving the patient responsible for self-administering an often complex regimen where adverse effects are common. Non-adherence and reduced relative dose intensity are both associated with poorer outcomes in the community setting but are rarely reported in clinical trials. The purpose of this study is to quantify adherence and relative dose intensity in oncology clinical trials and to determine patient and study related factors that influence adherence and relative dose intensity...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28454502/prediction-of-cardiovascular-risk-in-cancer-patients-of-south-india-using-who-ish-risk-prediction-charts-and-framingham-score-a-prospective-study
#8
M G Rajanandh, S Suresh, K Manobala, R Nandhakumar, G Jaswanthi, S Neha
Objective Despite the fact that cancer and heart diseases are interconnected, there is lack of information about the prevalence of cardiovascular risk in cancer patients in the South Indian population. With this background, the present study sought to predict the cardiovascular disease in cancer patients. Methods A prospective, cross-sectional study was conducted in the Department of Medical Oncology, Sri Ramachandra University and Hospital, India. Patients' demographic details, medical information, height, weight, body mass index, blood pressure, total cholesterol and HDL-cholesterol were measured...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28393590/feasibility-of-extended-dosing-intervals-of-denosumab
#9
Jacob K Kettle, Puja B Patel
Purpose Denosumab is a crucial supportive care agent for patients with advanced cancers affecting the bone. Despite the importance of treatment, logistical and financial obstacles hinder the ability to maintain long-term adherence. This analysis was designed to provide preliminary data regarding the feasibility of extended denosumab dosing intervals. Methods This retrospective, case cohort study was conducted on patients receiving treatment with denosumab for malignancies with bone involvement. A total of 60 patients were identified for analysis and were divided into cohorts according to the average number of days between denosumab doses...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28387636/assessing-the-need-for-improved-strategies-and-medication-related-education-to-increase-adherence-for-oral-anticancer-medications-in-the-young-adult-oncology-population
#10
Anupama Divakaruni, Elizabeth Saylor, Alison P Duffy
Rationale Oral anticancer medication adherence is a critical factor in optimizing cancer treatment outcomes and minimizing toxicity. Although potential adherence barriers exist, it is not well understood how these factors impact adherence. Methods This is a prospective, single-center, patient survey-based study conducted at the University of Maryland Greenebaum Comprehensive Cancer Center including 18- to 39-year-old patients who have been actively taking an oral anticancer medication for at least one month from 1 April 2013 to 1 April 2016...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28379068/impact-of-an-integrated-oral-chemotherapy-program-on-patient-adherence
#11
Katherine P Morgan, Benyam Muluneh, Allison M Deal, Lindsey B Amerine
As the use of oral chemotherapy continues to rise, the issue of patient adherence is a concerning aspect of cancer treatment. In this concurrent prospective and retrospective study, we assessed oral chemotherapy adherence in patients receiving their prescriptions at an institutional specialty pharmacy, with an integrated oral chemotherapy program. The primary endpoint is medication possession ratio. Secondary endpoints include self-reported adherence comparing survey data before and after the introduction of the oral chemotherapy program to assess the impact of the comprehensive pharmacy services provided...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28359173/recommendation-or-refusal-but-why-not-quality-of-surgery
#12
Mesut Tez, Baris Yildiz
No abstract text is available yet for this article.
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28358279/incidence-of-late-onset-neutropenia-associated-with-rituximab-use-in-b-cell-lymphoma-patients-undergoing-autologous-stem-cell-transplantation
#13
Vincent H Ha, Sunita Ghosh, Catherine Leyshon, Nikki Ryan, Carole R Chambers, Douglas A Stewart
Reversible late onset neutropenia associated with rituximab has been reported with incidence rates varying from 15 to 70% in B cell lymphoma patients receiving autologous stem cell transplantation. We conducted a retrospective descriptive study at one tertiary care center in adult B cell lymphoma patients treated with rituximab and autologous stem cell transplantation between 1 January 2004 and 30 June 2014. Late onset neutropenia was defined as an absolute neutrophil count <1.0 × 109  cells/L after neutrophil engraftment and less than six months post autologous stem cell transplantation...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28355971/could-knee-inflammatory-synovitis-be-induced-by-pembrolizumab
#14
Fade Mahmoud, John T Wilkinson, Alison Gizinski, Sanjaya Viswamitra, Neriman Gokden, John Vander Schilden
Pembrolizumab, a selective anti-PD-1 humanized monoclonal antibody, reactivates T cells to fight cancer. Immune-related adverse events such as autoimmune colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis may occur during, or weeks to months after therapy. Pemprolizumab-induced synovitis is rarely reported. With the wide use of immunotherapy to treat cancers, physicians need to be aware of this rare immune-related adverse event and provide immediate treatment to avoid permanent joint damage...
July 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29284362/a-retrospective-review-of-fall-risk-factors-in-the-bone-marrow-transplant-inpatient-service
#15
Cory M Vela, Lisa M Grate, Ali McBride, Steven Devine, Leslie A Andritsos
Purpose The purpose of this study was to compare medications and potential risk factors between patients who experienced a fall during hospitalization compared to those who did not fall while admitted to the Blood and Marrow Transplant inpatient setting at The James Cancer Hospital. Secondary objectives included evaluation of transplant-related disease states and medications in the post-transplant setting that may lead to an increased risk of falls, post-fall variables, and number of tests ordered after a fall...
June 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29284360/the-utility-of-routine-pre-chemotherapy-screening-with-cardiac-gated-blood-pool-scan-for-patients-at-low-risk-of-anthracycline-toxicity
#16
Puey Ling Chia, K Chiang, R Snyder, A Dowling
Background Anthracycline-based chemotherapy is used in many malignancies. Current recommendations by several groups suggest cardiac monitoring prior to and during anthracycline therapy. We aim to review the usefulness of baseline cardiac screening for left ventricular ejection fraction to assess if it had any impact on chemotherapy decisions in patients to be treated with anthracycline-based regimens or any beneficial effect upon outcomes. Methods We conducted a retrospective three-year audit of cancer patients who underwent GBPS prior to anthracycline (doxorubicin) chemotherapy...
June 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29284356/comparison-of-conditioning-regimen-toxicities-among-autologous-stem-cell-transplantation-eligible-multiple-myeloma-patients-high-dose-melphalan-versus-high-dose-melphalan-and-bortezomib
#17
Eda Aypar, Fikret Vehbi İzzettin, Şahika Zeynep Akı, Mesut Sancar, Zeynep Arzu Yeğin, Gülsan Türköz-Sucak
Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators. Objective In this retrospective study, we aimed to compare transplant-related toxicities and hematologic recovery of HDM and Bor-HDM conditioning regimens...
June 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29284347/real-world-treatment-patterns-in-chronic-myeloid-leukemia-patients-newly-initiated-on-tyrosine-kinase-inhibitors-in-an-u-s-integrated-healthcare-system
#18
Nazia Rashid, Han A Koh, Kathy J Lin, Brian Stwalley, Eugene Felber
Purpose To evaluate treatment patterns in patients diagnosed with incident chronic myelogenous leukemia (CML) newly initiating therapy with imatinib, dasatinib, or nilotinib. Patients were followed to determine switching and discontinuation rates. Factors associated with switching or discontinuation from index TKI therapy, reasons for discontinuation based on electronic chart notes, and frequency of laboratory monitoring were assessed during the follow-up period. Methods A retrospective cohort study was conducted in chronic myelogenous leukemia patients aged ≥ 18 years who were identified from the Kaiser Permanente Southern California (KPSC) Cancer Registry database during the study time period of 1 January 2007 to 12 December 2013...
June 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29284343/evaluation-of-a-medication-intensity-screening-tool-used-in-malignant-hematology-and-bone-marrow-transplant-services-to-identify-patients-at-risk-for-medication-related-problems
#19
Mariana Lucena, Carolyn Bondarenka, Genevieve Luehrs-Hayes, Andy Perez
Background In 2014, a screening tool was implemented at Medical University of South Carolina (MUSC) Health to identify patients who are at risk for medication-related events. Patients are classified as high-risk if they meet one of the following criteria: receiving anticoagulation therapy, taking more than 10 scheduled medications upon admission, or readmission within the past 30 days. The goal of this study was to determine risk criteria specific to the malignant hematology (MH) and bone marrow transplant (BMT) patients...
June 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28359174/chemotherapy-preparation-processes-methodological-issues-on-reliability-and-validity
#20
Siamak Sabour
No abstract text is available yet for this article.
June 2018: Journal of Oncology Pharmacy Practice
journal
journal
32324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"